Literature DB >> 11693750

Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein.

W F Penny1, O Ben-Yehuda, K Kuroe, J Long, A Bond, V Bhargava, J F Peterson, M McDaniel, J Juliano, J L Witztum, J Ross, K L Peterson.   

Abstract

OBJECTIVES: This study assessed coronary artery endothelial function in patients with hypercholesterolemia before and after lipid lowering, using quantitative angiography to examine the acetylcholine (Ach) response along the entire analyzable vessel.
BACKGROUND: Lipid lowering reverses endothelial dysfunction, but whether improvement occurs only in some segments and not others has not been established. Statistical correlation of improvement with specific lipid moieties remains undefined.
METHODS: Quantitative angiography was performed after Ach (10(-6), 10(-5), 10(-4) M) in 29 patients with coronary atherosclerosis before and 18 +/- 5.2 months after lipid-lowering treatment (statins, bile sequestrant resins). Standard lipid moieties and markers of oxidized low density lipoprotein (LDL) (immunoglobulin G and M autoantibody titers to malondialdehyde-LDL, E06 epitope) were measured serially.
RESULTS: Pre-treatment of the vessel diameters at control and with 10(-6)M, 10(-5) M and 10(-4) M Ach were 2.108 +/- 0.085, 2.086 +/- 0.087, 2.069 +/- 0.084 and 1.963 +/- 0.097 mm (M +/- SE), respectively, and increased at follow-up to 2.139 +/- 0.094, 2.119 +/- 0.086, 2.127 +/- 0.084 and 2.080 +/- 0.085 mm (p < 0.0001). Improvement in the most constricted and modest declination in the more dilated segments were observed. Change in the E06 and Apolipoprotein A-1 titers correlated with improved vasomotion (p = 0.027 and 0.005, respectively). The pre- and post-treatment levels of the E06 epitope, as well as the post-treatment IgM autoantibody titer to MDA-low density lipoprotein, also correlated (p < 0.028, < 0.001 and p < 0.004, respectively).
CONCLUSIONS: Drug treatment reverses endothelial dysfunction, but the effect is heterogeneous. Most coronary segments show enhancement, while others show declination of dilation, underscoring the importance of assessing the entire analyzable artery. Improvement in vasomotion correlates most significantly with markers of plasma-oxidized low-density lipoprotein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11693750     DOI: 10.1016/s0735-1097(00)01180-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  13 in total

Review 1.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 2.  Oxidized low-density lipoprotein biomarkers in atherosclerosis.

Authors:  Sotirios Tsimikas
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

3.  Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy.

Authors:  Ulrike Resch; Franz Tatzber; Alexandra Budinsky; Helmut Sinzinger
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

4.  Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia.

Authors:  Melinda D Wu; Federico Moccetti; Eran Brown; Brian P Davidson; Tamara Atkinson; J Todd Belcik; George Giraud; P Barton Duell; Sergio Fazio; Hagai Tavori; Sotirios Tsimikas; Jonathan R Lindner
Journal:  JACC Cardiovasc Imaging       Date:  2018-06-19

Review 5.  Oxidative modification of LDL: its pathological role in atherosclerosis.

Authors:  Hiroyuki Itabe
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

6.  Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome.

Authors:  Uma Singh; Sridevi Devaraj; Ishwarlal Jialal; David Siegel
Journal:  Am J Cardiol       Date:  2008-05-28       Impact factor: 2.778

Review 7.  Oxidative stress and endothelial dysfunction in vascular disease.

Authors:  Subramaniam Pennathur; Jay W Heinecke
Journal:  Curr Diab Rep       Date:  2007-08       Impact factor: 4.810

Review 8.  Lovastatin extended release: a review of its use in the management of hypercholesterolaemia.

Authors:  Monique P Curran; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension.

Authors:  Luciana Neves Cosenso-Martin; Luiz Tadeu Giollo-Júnior; Débora Dada Martineli; Cláudia Bernardi Cesarino; Marcelo Arruda Nakazone; José Paulo Cipullo; José Fernando Vilela-Martin
Journal:  Diabetol Metab Syndr       Date:  2015-08-26       Impact factor: 3.320

10.  The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD.

Authors:  Jonathan Watt; Simon Kennedy; Nadeem Ahmed; James Hayhurst; John D McClure; Colin Berry; Roger M Wadsworth; Keith G Oldroyd
Journal:  Open Heart       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.